2024-05-30 | SOPHARMA | SPH Consolidated financial report according to IFRS as at 31 March 2024 | 13,30 | 0,00 |
2024-05-27 | SOPHARMA | SPH Invitation and Materials for Annual General Meeting of Shareholders of Sopharma AD | 13,05 | +1,15 |
2024-05-21 | SOPHARMA | SPH Sales revenues for April 2024 | 13,05 | 0,00 |
2024-04-30 | SOPHARMA | SPH Individual financial report according to IFRS as at 31 March 2024 | 13,05 | 0,00 |
2024-04-25 | SOPHARMA | SPH Publication of Annual consolidated audited financial report of "Sopharma" AD for 2023 in ESF format | 13,05 | 0,00 |
2024-04-22 | SOPHARMA | SPH Sales revenues of Sopharma AD for March 2024 | 13,70 | 0,00 |
2024-04-01 | SOPHARMA | SPH Presentation of the Annual Audited Individual Financial Statements of “Sopharma” AD as at 31 December 2022 | 13,40 | 0,00 |
2024-03-20 | SOPHARMA | SPH Sales revenues for February 2024 | 14,40 | -3,13 |
2024-03-12 | SOPHARMA | SPH Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212 | 14,00 | -1,43 |
2024-03-11 | SOPHARMA | SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 08 March 2024 on the acquisition of shares from a capital increase | 13,80 | +1,45 |
2024-02-29 | SOPHARMA | SPH Consolidated financial report as of 31 December 2023 | 13,70 | -2,19 |
2024-02-27 | SOPHARMA | SPH Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212 | 13,40 | +2,99 |
2024-02-22 | SOPHARMA | SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the acquisition of shares from a temporary issue/exercise of warrants | 13,75 | -0,73 |
2024-02-22 | SOPHARMA | SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the exercise of warrants in a capital increase under the condition | 13,75 | -0,73 |
2024-02-20 | SOPHARMA | SPH NOTIFICATION OF INSIDERS’ TRANSACTIONS under art. 19 of Regulation 596/2014 for subscribin shares from a temporary issue/exercising warrants | 14,70 | -8,84 |
2024-02-20 | SOPHARMA | SPH Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 as of 20 February 2024 re exercising warrants | 14,70 | -8,84 |
2024-02-20 | SOPHARMA | SPH Notification from Ognian Donev under Art. 19 of Regulation (EU) 596/2014 for subscribing sharesd form a temporary issue/exercising warrants on 19 February 2024 | 14,70 | -7,48 |
2024-02-20 | SOPHARMA | SPH Notification from Ognian Donev in accordance with art. 19 from Regulation 596/2014 for exercising warrants on 19 February 2024 | 14,70 | -7,48 |
2024-02-19 | SOPHARMA | SPH Notification for Sales revenues for January 2024 | 14,65 | 0,00 |
2024-01-31 | SOPHARMA | SPH Technical error in the Notification under Art. 89t of the Law on Public Offering of Securities published on 26.01.2024 | 13,45 | 0,00 |
